IN SILICO CLINICAL TRIALS MARKET ANALYSIS
Global In Silico Clinical Trials Market: Key Developments
In July 2022, announced that the company has identified multiple unreported potential therapeutic targets for amyotrophic lateral sclerosis (ALS), using its proprietary Artificial Intelligence (AI) driven target discovery engine, PandaOmics. The findings were published in the June 28 issue of Frontiers in Aging Neuroscience.
In June 2022, announced ten highly innovative organizations joined its ground breaking Sensor Cloud Network, bringing high-quality data and data science together to help speed faster discovery and better treatments for patients.
In May 2022, GNS Healthcare announced a collaboration with Arvinas Inc., creating a new class of drugs based on targeted protein degradation to generate insights to help accelerate drug development for neurodegenerative diseases.
In December 2021, Novadiscovery (NOVA), expanded its collaboration with Janssen, to apply its collaborative clinical trial simulation platform, JINKO, to expand the existing lung cancer model to support Janssen’s market access and global medical affairs strategies.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 